CAT No: CP25557
CAS No: 200616-40-6
Synonyms/Alias: Fmoc-N-Me-Glu(OtBu)-OH;200616-40-6;Fmoc-N-methyl-L-glutamic acid 5-tert-butyl ester;(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid;MFCD00237028;(2S)-5-(tert-butoxy)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-5-oxopentanoic acid;Fmoc-L-MeGlu(tBu)-OH;Fmoc-N-Me-L-Glu(OtBu)-OH;n-methyl glutamic acid;Fmoc-MeGlu(OtBu)-OH;Fmoc-N-Me-Glu-(OtBu)-OH;Nalpha-Fmoc-Nalpha-methyl-L-glutamic Acid gamma-(tert-Butyl) Ester;SCHEMBL18291346;Fmoc-N-Me-Glu(OtBu)-OH, 97%;AKOS016002087;CS-W008529;DS-2294;HY-W008529;(2S)-5-tert-butoxy-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-5-oxo-pentanoic acid;AC-31988;Fmoc-Nalpha-methyl-L-glutamic acid gamma-t-butyl ester;Fmoc-Nalpha-methyl-L-glutamic acid gamma-t-butylester;S-200616-40-6;(2S)-5-(tert-butoxy)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}(methyl)amino)-5-oxopentanoic acid;(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-5-tert-butoxy-5-oxopentanoic acid;N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-alpha-methyl-L-glutamic-acid-gamma-t-butyl ester (Fmoc-N(Me)-L-Glu(OtBu)-OH);
Chemical Name: N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-alpha-methyl-L-glutamic-acid-gamma-t-butyl ester
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C25H29NO6 |
M.W/Mr. | 439.5 |
Sequence | Three Letter Code:Fmoc-N(Me)Glu(OtBu)(OtBu)-OH |
Application | Peptide synthesis; Drug screening |
Size | 1 g;5 g; |
InChI | InChI=1S/C25H29NO6/c1-25(2,3)32-22(27)14-13-21(23(28)29)26(4)24(30)31-15-20-18-11-7-5-9-16(18)17-10-6-8-12-19(17)20/h5-12,20-21H,13-15H2,1-4H3,(H,28,29)/t21-/m0/s1 |
InChI Key | FVUASVBQADLDRO-NRFANRHFSA-N |
Canonical SMILES | CC(C)(C)OC(=O)CCC(C(=O)O)N(C)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 |
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.